Premium
Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia
Author(s) -
Wróbel Grażyna,
Dobaczewski Grzegorz,
Patkowski Dariusz,
Sokół Agnieszka,
Grotthus Elżbieta
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21013
Subject(s) - medicine , splenectomy , refractory (planetary science) , recombinant factor viia , platelet , thrombocytopenic purpura , factor vii , immune thrombocytopenia , recombinant dna , surgery , purpura (gastropod) , coagulation , spleen , ecology , biochemistry , physics , chemistry , biology , gene , astrobiology
Approximately 5% of chronic immune thrombocytopenic purpura (ITP) manifests itself as symptomatic, severe thrombocytopenia requiring splenectomy. The surgical procedure increases the risk of serious hemorrhage, especially in patients refractory to platelet transfusions. Recombinant factor VIIa (rFVIIa) has been found to enhance thrombin generation on activated platelets and may be a promising agent in preventing life‐threatening bleedings. The administration of rFVIIa in two patients with severe refractory ITP, who underwent splenectomy, is presented. Combined therapy with agents of different mechanisms of action could be useful in cases with the highest probability of bleeding. Pediatr Blood Cancer 2006;47:729–730. © 2006 Wiley‐Liss, Inc.